Novel method for generating antibodies could revolutionize Alzheimer’s and Parkinson’s research

In diseases like Parkinson’s and Alzheimer’s, specific proteins misfold and clump together, forming toxic aggregates that damage brain cells.

Risk adjusted net present value: What is the current valuation of Avidity Biosciences’s AOC-1020?

AOC-1020 is an antisense rnai oligonucleotide commercialized by Avidity Biosciences, with a leading Phase II program in Facioscapulohumeral Muscular Dystrophy (FSHD).

December 14, 2024

Judge rules against AstraZeneca in suit over IRA price negotiations

A federal judge in Delaware on Friday ruled in favor of the Biden administration in a case brought by AstraZeneca seeking to overturn parts of

March 2, 2024

Targeting FGFR mutations offers new hope for bone repair in skeletal disorders

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely

February 21, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.